Welcome to our dedicated page for Intellia Therape news (Ticker: NTLA), a resource for investors and traders seeking the latest updates and insights on Intellia Therape stock.
Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a clinical-stage gene editing company whose news flow centers on the development of CRISPR-based therapies. Company announcements frequently highlight progress in its in vivo programs, including nexiguran ziclumeran (nex-z) for transthyretin (ATTR) amyloidosis and lonvoguran ziclumeran (lonvo-z) for hereditary angioedema (HAE). Investors following NTLA news can see updates on clinical trial data, regulatory interactions and platform developments that shape the company’s pipeline.
Recent Intellia press releases and SEC-furnished materials describe longer-term Phase 1 and Phase 1/2 data for nex-z and lonvo-z, pooled analyses of patient outcomes, and details from global Phase 3 trials such as MAGNITUDE, MAGNITUDE-2 and HAELO. News items also cover events such as temporary pauses in patient dosing, FDA clinical holds on Phase 3 nex-z trials, and subsequent company plans to work with regulators. These disclosures provide insight into both the potential and the risks associated with Intellia’s CRISPR-based candidates.
Beyond clinical results, NTLA news includes quarterly financial updates, equity inducement grants under Nasdaq Listing Rule 5635(c)(4), and investor presentations at major healthcare conferences. Together, these items give a view into Intellia’s operational progress, capital position and strategic priorities as it advances gene editing therapies for serious diseases like ATTR amyloidosis and HAE.
This news page aggregates Intellia’s latest press releases and related market-moving information in one place, allowing readers to review clinical milestones, regulatory developments and corporate updates linked to the NTLA stock.
Intellia Therapeutics (NASDAQ:NTLA) announced updated preclinical data on CRISPR/Cas9-mediated gene insertion for treating alpha-1 antitrypsin deficiency (AATD) at the ASGCT Annual Meeting, held virtually from May 11-14, 2021. The findings suggest a potential to restore normal AAT protein levels after a single dose, showcasing Intellia's commitment to innovative treatments. Presentations from key executives will cover topics such as genome editing strategies and on-target safety assessments. Further information is expected to be released during the meeting.
Intellia Therapeutics (NASDAQ: NTLA) has appointed Dr. Georgia Keresty to its Board of Directors, enhancing its leadership team. Dr. Keresty brings over 35 years of pharmaceutical experience, having held senior roles in leading companies like Takeda, Johnson & Johnson, and Bristol-Myers Squibb. Her expertise encompasses transitioning therapeutic programs to clinical development and improving manufacturing processes. Intellia aims to leverage her knowledge as it advances its CRISPR/Cas9 technology towards curative therapies.
Intellia Therapeutics (NASDAQ:NTLA) has received orphan drug designation from the European Commission for NTLA-2001, aimed at treating transthyretin amyloidosis (ATTR). This investigational CRISPR therapy is the first of its kind to be delivered systemically via intravenous dosing, targeting the TTR gene responsible for producing misfolded proteins. This milestone is significant for the ATTR community, where no existing cure is available. The therapy shows potential to halt and reverse ATTR progression and is part of a co-development agreement with Regeneron.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is set to present its first preclinical data on a new cytosine deaminase base editor technology at the Cold Spring Harbor Laboratory virtual meeting, running from March 24-26, 2021. The data highlights the ability of the company’s proprietary base editors to enable multiple gene knockouts without increasing translocation rates. CEO John Leonard emphasizes the expansion of their genome editing platform for developing therapies for severe diseases. The presentation details include an impressive T cell editing efficiency of over 90% while maintaining standard translocation levels.
Intellia Therapeutics (NASDAQ: NTLA) showcased promising preclinical data on March 10, 2021, regarding non-viral genome editing of hematopoietic stem cells (HSCs) in mouse models. This innovative approach aims to address inherited blood disorders such as sickle cell disease (SCD). Key findings included durable, dose-dependent gene editing in bone marrow and HSCs, with effects lasting over a year. Intellia's proprietary lipid nanoparticles facilitated the safe delivery of CRISPR/Cas9, potentially revolutionizing treatment options for patients globally without the need for invasive procedures.
Intellia Therapeutics (NASDAQ:NTLA) reported operational and financial results for Q4 2020, ending with a cash position of $597.4 million. The company successfully dosed its first patient with NTLA-2001, a CRISPR-based therapy for transthyretin amyloidosis (ATTR). It expects to report initial clinical data on NTLA-2001 this year and plans to submit IND applications for NTLA-5001 (AML) and NTLA-2002 (HAE) in mid-2021. R&D expenses increased to $38.2 million, while net loss was $42.2 million for Q4 2020, compared to $28.3 million in Q4 2019.
Intellia Therapeutics (NASDAQ:NTLA) will announce its fourth quarter and full-year 2020 financial results on February 25, 2021, at 8 a.m. ET. The company focuses on developing curative therapeutics utilizing CRISPR/Cas9 technology for both in vivo and ex vivo applications. Interested participants can join the conference call by dialing the provided numbers. A replay of the call will be available later that day on the company's website. Intellia's mission is to produce permanent gene edits and engineered cells to treat various diseases.
Intellia Therapeutics (NASDAQ:NTLA) is advancing its global Phase 1 study of NTLA-2001, a single-course therapy for transthyretin amyloidosis (ATTR). The company plans to submit an IND for NTLA-5001, targeting acute myeloid leukemia (AML), by mid-2021, and another IND for NTLA-2002 for hereditary angioedema (HAE) in the second half of 2021. Intellia also aims to nominate at least one new candidate in 2021. With a strong cash position of $597 million at the end of 2020, the company is well-positioned to fund operations for the next 24 months.
Intellia Therapeutics (NASDAQ:NTLA) announced progress in its gene therapy for alpha-1 antitrypsin (AAT) deficiency at the Alpha-1 Foundation’s workshop. The company demonstrated that a single course of its CRISPR/Cas9-based therapy can durably restore human AAT protein levels in non-human primates. This innovative approach could offer a potentially curative treatment for AAT deficiency, which causes liver and lung dysfunction. The stable AAT levels observed over 11 weeks indicate the treatment's promise, reinforcing Intellia's commitment to advancing its genome editing technologies for rare genetic disorders.
Intellia Therapeutics presented promising preclinical results for NTLA-5001, a TCR-T cell therapy targeting WT1 in acute myeloid leukemia (AML), at the 62nd ASH Annual Meeting. The lead candidate demonstrated superior anti-tumor activity in mouse models compared to standard methods. The company plans to submit an IND application in H1 2021 and initiate a first-in-human trial to assess safety and efficacy in AML patients. NTLA-5001 aims at treating AML patients irrespective of genetic subtypes, with potential future applications for WT1-positive solid tumors.